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INTRODUCTION
Auditory processing disorder (APD) is characterized by deficits in the perception of
speech sounds, often leading to difficulties understanding speech in noisy environments.
Individuals with APD have normal hearing thresholds and hearing ability, yet have difficulty
distinguishing between similar sounds and inability to follow oral instruction. Affected
individuals are easily distracted by background noise, and have trouble paying attention to verbal
stimuli and comprehending complex sentences. Due to these impairments, academic
performance and quality of life are often negatively impacted (BSA, 2011; Moore et al., 2013).
Although there is an ongoing debate regarding the definition of APD, it is believed that APD
stems from neural anomalies in central auditory processing and may include difficulties in
complex acoustic tasks (i.e., sound localization, pattern recognition, and temporal
discrimination) (ASHA, 2005).
Over the past several years, there has accumulated a growing catalog of evidence
supporting APD as a neurodevelopmental disorder. Children diagnosed as APD display
symptoms that emerge throughout the course of development (Moore et al., 2006), bearing a
striking resemblance to other developmental disorders (i.e., dyslexia and specific language
impairment (SLI)). Additionally, APD -- like several other developmental disorders -- is
diagnosed only when a child fails to obtain typical levels of functioning within a specific
domain, and in the absence of other known environmental causal factors (i.e., deafness,
blindness, and low socio-economic status). Thus, APD diagnosis is typically made only when
auditory processing deficits cannot be explained by hearing impairment or deafness (Witton et
al., 2010).
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APD is, however, comorbid with various learning and language-related disorders, and
nearly 50% of children diagnosed with APD fit a diagnosis of dyslexia, SLI, or both. (Dawes &
Bishop et al., 2010). For instance, Sharma et al., (2009) reports that 67% of children with APD
had language and reading problems, further supporting a relationship between ADP and
language-related disorders. Yet, APD is not restricted to language-related disorders. Reports
have shown that APD also shares significant overlap with attention-deficit disorder (ADD)
(Gascon et al., 1986; Cook et al., 1993).
APD lacks a clear definition and diagnosis (as discussed above). This can be attributed to
a failure to identify causal mechanisms, including whether the core deficits of APD arise from
sub-clinical hearing impairments, atypical auditory processing and integration, comorbid
cognitive disabilities (i.e., attention), or a combination. Furthermore, genetic contributions to
APD are poorly understood (Witton et al., 2010). Genetic studies of APD are in preliminary
stages, but evidence suggests that auditory processing traits can be inherited. A recent study by
Brewer et al., (2016) showed significant evidence of genetic influence on non-speech auditory
processing skills (i.e., temporal processing, frequency discrimination, and spectral processing),
supporting the view that genetic variation can influence auditory processing. It is worth noting
that Brewer et al., measured the heritability of non-speech auditory processing skills, but did not
access measures of speech-related auditory processing – a key component in diagnosing APD
(Emanuel et al., 2011). Nonetheless, studies like these can be used to create a frame work for
identifying APD-risk genes.
One syndrome with promising connection to APD is Usher Syndrome (USH), a
monogenic recessive disorder associated with combined bilateral hearing loss and vision loss
caused by retinitis pigmentosa (RP). It is estimated that 4 in 100,000 individuals are affected by
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USH (Boughman et al., 1983; Keats et al., 1999). Three forms of USH are observed in patients,
including USH types 1 - 3 (USH1 - 3). USH1 represents a more severe version of Usher
syndrome, where individuals are born deaf and RP begins pre-puberty (Otterstedde et al., 2001).
USH2 patients show moderate-to-severe hearing loss, with RP beginning during puberty (Reisser
et al., 2002). USH3 is highly variable with respect to the onset and progression of hearing and
visual impairments (Pakarinen et al., 1995). Extensive research has been aimed at determining
and identifying causal genes associated with all three forms of Usher syndrome. To date,
evidence suggests that inner ear hair cell development and retinal photoceptor stability contribute
to phenotypes associated with Usher syndrome (Ahmed et al., 2013; Cosgrove et al., 2013; Pan
et al., 2012; Williams et al., 2008).
Thirteen genes have been associated with Usher syndrome – six of which have been
associated with USH1 (MYO7A, USHIC, CDH23, PCDH15, USH1G, and CIB2) (Weil et al.,
1995; Weil et al., 2003; Verpy et al., 2000; Bolz et al., 2001; Alagramam et al., 2001; Riazuddin
et al., 2012), three associated with USH2 (USH2A, GPR98, and DFNB31) (Eudy et al., 1998;
Weston et al., 2004; Ebermann et al., 2007), two associated with USH3 (CLRN1 and HARS)
(Puffenberger et al., 2012), and one atypical USH gene (PDZD7) (Ebermann et al., 2010).
Although USH genes are expressed in various tissues (Bhattacharya et al., 2002; Pearsall et al.,
2002), protein expression is strongly localized to the retina and inner ear hair cell. USH2A,
which is responsible for roughly 55% - 90% of USH2 cases (Dreyer et al., 2008; Millán et al.,
2011), is expressed throughout the body, including the cochlear, retina, small and large intestine,
trachea, testis, and ovary, but excluding brain (Pearsall et al., 2002).
Based on Usher syndrome’s association with hearing loss, evidence suggests that USH2
shares a genetic etiology with APD. As mentioned above, homozygous mutations of USH2A are

3

associated with non-progressive, moderate-to-severe hearing loss and progressive RP (as seen in
USH2). It is important to note that as it stands, individuals with heterozygous mutations of
USH2A are thought to be phenotype-free and are considered unaffected carriers. However,
limited research on hearing in carriers of USH2 did find that carriers had sensorineural hearing
loss at low frequencies, while individuals diagnosed with USH2 displayed the expected and
stereotypical high frequency hearing loss (van Aarem et al., 1995). With the exception of this
and a few scattered studies studies (Sondheimer et al., 1979; Kloepfer et al., 1966; Haas et al.,
1970), anomalies in USH2 carriers remain largely ignored, and the field at large continues to
treat USH2 as an exclusively autosomal recessive disorder.
To further validate USH2A as a candidate-risk gene for APD, Perrino et al., (in-prep)
ascertained a nuclear family, all of whom were direct descendants of an individual diagnosed
with APD. Affected individuals displayed characteristics similar to those of APD – i.e.,
problems with hearing speech sounds in the presence of background noise, a slow, distinct and
deliberate style of speech, and severe language comprehension deficits, yet, all had normal
hearing thresholds. Whole genome sequencing of two of the family members revealed a stopgain mutation in the USH2A gene (chr1:215847632, G>A (hg19), NP_996816:p.Gln4541*)
shared by all affected family members. This variation, in combination with a pathogenic variant,
was previously reported as pathogenic in a unique Usher syndrome case (Le Quesne Stabej et al.,
2012). Together, these results suggest a relationship between USH2A, APD and language
development.
Usherin, the protein product of USH2A, is found in the basement membrane of
differentiating stereocilia acting as a lateral ankle link connecting adjacent stereocilia (Adato et
al., 2005). Research conducted by Liu et al., (2007) furthered our understanding of usherin, with
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data showing that usherin is essential for postnatal maturation of cochlear hair cells. During the
development of the cochlea, kinocilium provide important positional cues for subsequent
stereocilia development. Once the cochlea reaches maturation, kinocilium recede, leaving
stereocilia in their correct, final location. Lui et al., suggested that usherin is involved in this
interaction between stereocilia and kinocilium, as well as the interaction between adjacent
stereocilia. Results from a mouse model of Usher syndrome, involving a knockout of the rodent
homolog of USH2A (Ush2a) revealed that loss of usherin results in the disorganization of outer
cochlea hair cells. This could explain the hearing loss associated with USH2 (Liu et al., 2007), as
well as a potential relationship with APD (i.e., central auditory processing abnormalities).
The current study was designed to further explore the relationship between USH2A, ADP
and language development, with an emphasis on auditory processing ability. Previous studies of
Ush2a KO mice have already reported morphological abnormalities within the cochlea.
Specifically, the localization of usherin in all outer hair cell layers of the cochlea was absent in
KO mice, resulting in a lack of outer hair cells in the basal cochlea. Additionally, mean cochlear
thresholds by measure of DPOAEs indicated hearing loss for high-frequency sounds (>20,000
Hz) in Ush2a KO mice. This phenotype was observed at both 4 and 7 months, suggesting the
observed high-frequency hearing loss was non-progressive -- a phenotype consistent with human
USH2 (Liu et al., 2007). Although these studies provided excellent measures of morphological
differences between wildtype (WT) and Ush2a KO mice, they failed to examine how a
heterozygous mutation of USH2A might impact hearing and auditory processing ability. Our
goal was to further explore the relationship between USH2A, ADP and language development,
by examining both Ush2a heterozygous (HT) and KO mice on a battery of rapid auditory
processing tasks, as well as completing a characterization of their ultrasonic vocalizations.
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Strong evidence suggests that rapid auditory processing (RAP) ability is associated with
language development, and deficits in RAP ability are robust predictors of deficits in language
ability in humans (Choudhury et al., 2007; Benasich & Tallal, 2002; Benasich et al., 2006). The
results presented here suggest that studies of USH-related genes can provide a novel approach to
understanding the genetics associated with auditory processing disorder, with implications for
screening both APD and language outcomes.
METHODS
Subjects
Six Ush2a knockout (KO) male mice were provided by Dr. Jun Yang (University of
Utah; Liu et al., 2007), and were re-derived on an 129S4/SvJaeJ background strain at the Gene
Targeting and Transgenic Facility (GTTF) at UConn Health. F1 subjects were delivered to the
University of Connecticut where they were crossed with six wildtype (WT) controls
(129S4/SvJaeJ; stock number 009104) purchased from The Jackson Laboratory (Bar Harbor,
ME). The resulting F2 offspring were heterozygous (HT) for the Ush2a gene. Breeding pairs
(HT x HT) were used to generate the experimental subjects, such that all genotypes
(homozygous knock-out, heterozygous, and wildtype) were represented within-litter (F3). F3
genotypes were determined via PCR of ear punch DNA using the following primers: Common
(5’ – GTGAATACAGGCACCTCTGAATGTGAC – 3’), WT (5’ –
GTCACGGCTGAATCCCGAAGC – 3’), KO (5’ – GAGATCAGCAGCCTCTGTTCCAC – 3’).
Twelve WT male mice, 12 HT male mice, and 11 Ush2a KO male mice from F3 were randomly
selected in adulthood for behavioral testing. All subjects were single housed in standard
Plexiglass mouse-tubs (12hr / 12hr light-dark cycle), with food and water available ad libitum.
Behavioral testing was performed blind to subject genotype. All procedures were conducted in
6

compliance with the Guide to the Care and Use of Laboratory Animals and was approved by the
University of Connecticut’s Institutional Animal Care and Use Committee (IACUC).
Auditory Processing (Postnatal day (P)65 – P112)
Modified Prepulse Inhibition Paradigm
Following puberty, subjects were tested on a battery of auditory processing tasks using a
modified prepulse inhibition paradigm (see Fitch et al., 2008 for review). The ability to suppress
an acoustic startle response (ASR; an involuntary, reflexive response to an unexpected auditory
stimulus [startle eliciting stimulus (SES); 105dB, 50ms, broadband white noise burst (1 kHz – 10
kHz)]) was measured. Subjects were placed on cell-loaded platforms (Med Associates, St.
Albans, VT), and presented with varying auditory stimuli generated via RPvdsEx software and a
RZ6 multifunction processor (Tucker Davis Technologies, Alachua, FL). Subject motor reflex
responses were recorded via a Biopac MP150 acquisition system and Acqknowledge 4.1
software (Biopac Systems, Goleta, CA) connected to the load cell platforms. During cued trials,
subjects were presented with an auditory cue (prepulse) 50ms before the presentation of the SES
(no cue presentation occurred during uncued trials). If the subject was able to detect the auditory
cue, an attenuation (or reduction) of their ASR was expected relative to their ASR during an
uncued trial. If the auditory cue was not detected, the response was expected to equate to an
uncued trial. Quantification of this phenomenon was termed the “attenuation score” (ATT),
which compared the mean amplitude of cued ASR to that of the uncued ASR for each subject,
for each session condition.
𝑚𝑒𝑎𝑛 𝑐𝑢𝑒𝑑 𝐴𝑆𝑅
𝑥 100
𝑚𝑒𝑎𝑛 𝑢𝑛𝑐𝑢𝑒𝑑 𝐴𝑆𝑅
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Normal Single Tone
Subjects were first tested on Normal Single Tone (NST) to measure baseline prepulse
inhibition, general auditory ability, and to rule out any underlying auditory processing
impairments that might impede performance on subsequent auditory processing tasks (i.e.,
impaired reflex mechanics). Subjects were required to detect a simple single tone (50ms, 75dB)
against a silent background. This cue was presented 50 ms before the SES on half of the trials
(104 cued and uncued trials in total, pseudorandom and evenly distributed), at inter-trial intervals
(ITI) ranging from 16s – 24s. Two versions of this task were developed – a 15kHz version (cue;
50ms, 75dB, 15,000 Hz tone) and a 40 kHz version (cue; 50ms, 75dB, 40,000 Hz tone). All
subjects were able to perform both versions of the task (15 kHz – P65; 40 kHz – P103). The
frequency-matched NST score for each subject was used as a covariate in the analysis of further
tasks, specifically to eliminate individual differences in PPI or hearing from subsequent auditory
processing analyses.
Embedded Tone
The variable duration Embedded Tone Task (EBT) consisted of 300 pseudorandom trials
with ITIs ranging from 16s – 24s. Subject’s ability to detect a change in tone frequency from a
constant pure-tone background was measured, and ATT scored were calculated. During cued
trials, a single cue was presented 100ms before the SES; for uncued trials, the “cue” was
presented 0ms before the SES (i.e., no cue). Three versions of this task were used: 1) a longduration EBT task, where the cue duration ranged from 0ms – 100ms (cue; 75dB, 5600 Hz tone
& pure-tone background; 75dB, 10,500 Hz tone); 2) a short-duration EBT task, where the cue
duration ranged from 0ms – 10ms (cue; 75dB, 5600 Hz tone & pure-tone background; 75dB,
10,500 Hz tone); 3) an ultrasonic long-duration EBT task where the cue duration ranged from
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0ms – 100ms (cue; 75dB, 35,000 Hz tone & pure-tone background; 75dB, 40,000 Hz tone). This
combination of frequencies and temporal durations was designed to capture the range of
processing capacities, allowing us to test for genotype-specific differences in that range. Nonultrasonic and ultrasonic versions of the task were necessary to determine any Genotype effects
observed were frequency dependent. Both non-ultrasonic versions of the task were administered
for five consecutive days, and the ultrasonic version of the task was administered for four
consecutive days (EBT 100: P68 – P72; EBT 10: P75 – P79; EBT 100 at 40kHz: P104 – P107).
Silent Gap
The Silent Gap (SG) task was used to evaluate the ability to detect silent breaks (or silent
gaps) in a continuous white noise background (75dB, 100 Hz – 10,000 Hz). Each testing session
consisted of 300 pseudorandom cued or uncued trials, with an ITI ranging from 16s – 24s.
During cued trials, a silent gap was presented 100ms before the SES. The cue durations ranged
from 0ms – 300ms (SG 0-300) or 0ms – 100ms (SG 0-100). For uncued trials, the silent gap
consisted of a 0ms cue. Each version of the task (SG 0-300 and SG 0-100) was conducted for
five consecutive days (SG 300: P82 – P86; SG 100: P89 – P93).
Pitch Discrimination
Pitch Discrimination (PD) testing assessed the subject’s ability to detect subtle changes in
pitch within a constant pure-tone background. Each testing session consisted of 300
pseudorandom trials, with an ITI ranging from 16s – 24s. During cued trials, the cue was
presented for 300ms, 100ms before the SES. “Cues” presented during uncued trials were
presented at the same frequency as the pure-tone background. Two versions of this task were
used for this study: 1) PD task where the cue frequency deviated 5 Hz – 75 Hz above or below a
10,500 Hz pure-tone background (cue: 300ms, 75dB tone & pure-tone background: 10,500Hz
9

tone); and 2) ultrasonic PD task where the cue frequency deviated 5 Hz – 75 Hz above or below
a 40,500 Hz pure-tone background (cue: 300ms, 75dB tone & pure-tone background: 40,500Hz
tone). A non-ultrasonic PD task was administered for five consecutive days, and an ultrasonic
PD task was administered for three consecutive days (PD: P96 – P100; PD at 40kHz: P110 –
P112).
Ultrasonic Vocalizations (USVs; P117 – P121)
Following assessment of auditory processing ability, ultrasonic vocalizations (USVs)
were recorded and analyzed using methods adapted from Chabout et al., 2017. Using WT
female homecage bedding and urine collected 5 days prior to testing, a single experimental male
mouse was placed in a standard Plexiglass tub with a single novel WT female mouse and
allowed to freely interact for 5 minutes. In this setting, a male mouse will vocalize while the
female does not, such that recoded calls can be attributed to the male. A Brüel & Kjær Type
4954-B microphone (Brüel & Kjær, Nærum, Denmark), connected to a RME Fireface UC audio
interface (RME Audio, Haimhausen, Germany), was placed 5cm above the top of the Plexiglass
tub. USVs were recorded at 192,000 Hz using DIGICheck 5.92 (RME Audio, Haimhausen,
Germany) to ensure all USVs were captured. Following USV recording, sound files (.wav) were
analyzed in MATLAB (MathWorks) using MUPET (Mouse Ultrasonic Profile ExTraction (Van
Segbroeck et al., 2017). Syllables in the range of 35,000 Hz to 110,000 Hz, and durations
between 8 ms to 200 ms, were analyzed. If syllables occurred less than 5 ms apart, they were
excluded from analyses. Following these parameters, a syllable repertoire was generated,
illustrating 40 unique syllables (Figure 1). These 40 unique syllables were then assigned to one
of ten potential syllable categories, as defined by Heckman et al., 2016. From our subjects, only
eight of the ten possible categories were produced; Short, Down-FM, Up-FM, Chevron, Flat, 1-
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Freq Step, Noisy, and Complex -- 2-Frequency Step and Reverse Chevron were not observed
(Heckman et al., 2016). Total time spent vocalizing (s), Duration of syllables (ms), and the
mean frequency (kHz) of each syllable was exported from MUPET and used for statistical
analyses.
Auditory Processing – Statistical Analysis
Normal Single Tone attenuation scores were analyzed using a one-way analysis of
variance (ANOVA) comparing WT, HT, and Ush2a KO performance. To account for individual
variation in baseline prepulse inhibition and hearing, NST was used a covariate for subsequent
statistical analyses (NST 15 kHz was used as a covariate for all non-ultrasonic auditory tasks;
NST 40 kHz was used as a covariate for all ultrasonic auditory tasks). EBT, SG, and PD tasks
were analyzed using a mixed factorial design. Differences in ATT scores for non-ultrasonic
EBT 100 and EBT 10 were conducted using a 3 x 5 x 9 repeated measures ANCOVA, with
Genotype (three levels; WT, HT, Ush2a KO) as the between-subjects variable, and Day (five
levels) and cue Duration (nine levels) as the within-subjects variables. Ultrasonic EBT 100 data
was analyzed using a 3 x 4 x 5 repeated measures ANCOVA with Genotype (three levels) as the
between-subjects variable, and Day (four levels) and cue Duration (five levels) as the withinsubjects variables. Similar to non-ultrasonic EBT, SG 300 and SG 100 were analyzed using 3 x 5
x 9 repeated measures ANCOVA, with Genotype (three levels; WT, HT, Ush2a KO) as the
between-subjects variable, and Day (five levels) and cue Duration (nine levels) as the withinsubjects variables. For Pitch Discrimination, a 3 x 5 x 9 and a 3 x 3 x 5 (for non-ultrasonic PD
and ultrasonic PD, respectively) repeated measures ANCOVA was used to determine ATT
differences, where Genotype (three levels) was the between-subject variables and Day (five
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levels, three levels) and Frequency (nine levels, five levels) were the within-subject effects.
Statistical analyses were completed used SPSS 24 with an alpha criterion of 0.05.
Ultrasonic Vocalizations – Statistical Analysis
The time spent vocalizing, number of calls produced, duration of syllables produced,
volume of calls, and mean frequency of calls (both overall and collapsed across syllable
category) was analyzed using a one-way analysis of variance (ANOVA) comparing WT, HT,
and Ush2a KO scores.
RESULTS
Auditory Processing
Ush2a HT, KO, and WT control mice were tested on a series of acoustic detection tasks
adapted to a prepulse inhibition (PPI) paradigm, specifically to index hearing and complex
acoustic discrimination (Fitch et al., 2008). Subjects were first assessed for detection of purefrequency tones of variable frequency (15 or 40 kHz) via PPI reflex. Results at 15kHz showed
that Ush2a HT mice were significantly worse than both WT controls and Ush2a KOs [(Overall):
F(2,32) = 3.697, p < 0.05; (WT vs. HT): F(1, 22) = 3.201, p < 0.10], while WT and Ush2a KO
did not differ [(WT vs. KO): F(1, 21) = 1.054, p > 0.05; (HT vs. KO): F(1, 21) = 5.016, p < 0.05]
(Figure 2). At 40kHz, Ush2a HT mice performed similarly to WT control, whereas Ush2a KO
mice trended to the expected impairment [(Overall): F(2,32) = 1.995, p < 0.1, one-tail; (WT vs.
HT): F(1, 22) = 0.619, p > 0.05; (WT vs. KO): F(1, 21) = 3.125, p < 0.10; (HT vs. KO): F(1, 21)
= 1.517, p > 0.05] (Figure 2). In order to determine whether higher-order acoustic deficits
reflected simple hearing loss, individual scores on this single tone task (frequency-matched)
were used as a covariate for analysis of complex tasks. Findings showed that even when lowlevel hearing loss was factored out, using NST as a covariate, deficits were still evident for HT
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mice on complex low frequency tasks [Embedded Tone 100: 10.5 kHz (Overall): F(2, 31) =
3.691), p < 0.05; (WT vs. HT): F(1, 21) = 3.634, p < 0.10; (WT vs. KO): F(1, 20) = 0.691, p >
0.05; (HT vs. KO): F(1, 20) = 6.845, p < 0.05] (Figure 3), [Embedded Tone 10: 10.5 kHz
(Overall): F(2, 31) = 4.635, p < 0.05), (WT vs. HT): F(1, 21) = 2.798, p =0.10; (WT vs. KO);
F(1, 20) = 1.769, p > 0.05; (HT vs. KO): F(1, 20) = 13.320, p < 0.05] (Figure 4), [Embedded
Tone 100: 40 kHz (Overall): F(2, 31) = 0.948, p > 0.05] (Figure 5). KO mice displayed deficits
on higher frequency tasks [Pitch Discrimination: F(2, 31) = 1.325, p > 0.05] (Figure 6),[Pitch
Discrimination: 40.5 kHz (Overall): F(2, 31) = 2.335, p > 0.05; (WT vs. HT): F(1, 21) = 0.247, p
> 0.05; (WT vs. KO): F(1, 20) = 9.232, p < 0.05; (HT vs. KO): F(1, 20) = 1.657, p > 0.05]
(Figure 7). There were no genotype differences on SG tasks [Silent Gap 300: F(2, 31) = 2.497, p
> 0.05] (Figure 8), [Silent Gap 100: F(2, 31) = 1.378, p > 0.05] (Figure 9).
Ultrasonic Vocalizations
Ultrasonic vocalizations (USVs) were recorded from Ush2a HT, KO, and WT mice and
analyzed to determine Genotype-based differences in USV properties, including time spent
vocalizing, number of calls, duration of syllables, volume of produced syllables and pitch. There
were no significant Genotype differences on total time spent vocalizing [F(2, 237) = 0.6304, p >
0.05] (Figure 10) and total number of calls produced [F(2, 269) = 1.3808, p > 0.05] (Figure 11).
No call-specific analyses showed overall or pair-Genotype effects for time spent vocalizing and
number of calls. However, Ush2a HT mice produced significantly shorter calls than WT mice
[F(2, 16100) = 26.70, p < 0.05] (Figure 12). Additionally, Ush2a HT mice produced USVs with
significantly more energy than WT mice (a measure of syllable volume) [F(2, 16100) = 142.54,
p < 0.05] (Figure 13). Finally, results showed that Ush2a HT mice vocalized at significantly
higher frequencies (pitch) [F(2, 16100) = 87.476, p < 0.05] (Figure 14. (See Tables 1, 2, and 3
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for a compressive statistical summary of duration of syllables, volume of produced syllables, and
frequency of produced syllables. The syllable repertoire generated by MUPET can be seen in
Figure 1).
Together, these findings indicate that heterozygous disruption of the Ush2a gene
associates with low-frequency hearing loss, a phenotype distinct from the high-frequency hearing
loss characterizing Usher syndrome in humans, as well as the phenotype observed in KO mice.
The low-frequency hearing loss in HTs was further associated with higher-order auditory
processing deficits, even after co-varying for the hearing loss. Moreover, this low-frequency
hearing loss was associated with modifying effects (possibly developmental) on adult expressive
vocalizations.
DISCUSSION
We assessed rapid auditory processing (RAP) ability and conducted a complete
characterization of ultrasonic vocalizations (USV) in a mouse model of Usher syndrome type 2
in efforts to better understand the relationship between the USH2A gene, and auditory processing
disorder (APD), with implications (in humans) for language development. Results showed that
Ush2a KO mice displayed the expected high frequency hearing loss, as seen on NST 40 kHz and
PD 40 kHz tasks, while Ush2a HT mice displayed low-frequency hearing loss on NST 15 kHz
and frequency-driven deficits on low-frequency RAP tasks (i.e., EBT 100 at 10.5 kHz and EBT
10 at 10.5 kHz). Ush2a HT and KO mice did not show deficits or impairments on temporallydriven RAP tasks (i.e., SG 300 and SG 100), suggesting that the auditory processing impairments
are restricted to the frequency domain. Additionally, Ush2a HT mice produced USVs that were
shorter in duration and at a higher frequency than WT mice. Not only do these findings support
the role of USH2A in high-frequency hearing loss, consistent with the diagnostic criteria for
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USH2, but they introduce a novel phenotype for USH2 carriers – heterozygous mutations of
USH2A result in low-frequency, low-level hearing loss, which in-turn leads to higher-order
auditory processing deficits, coupled with communicative deficits.
Ush2a HT mice produce shorter ultrasonic vocalizations (USV) at higher-frequencies
than WT mice. Recent research in studying and understanding mouse USVs revealed that these
calls reflect the emotional and behavioral state of the mouse (Chabout et al., 2012), as male mice
have been shown to produce context-specific USVs. The lack of significant differences between
WT, HT and KO Ush2a mice on measures of time spent vocalizing and number of calls could
suggest that these mice do not display social deficits. However, because differences in the
duration of call types, frequency of calls, and the volume of the produced calls were seen in
Ush2a HT mice, we have reason to believe that expressive communication ability was impaired.
These results parallel human clinical findings in which USH carriers (heterozygous for the
mutation) have a distinct style of speech (Perrino, in-prep). The alterations in vocalizations may
be a consequence of the auditory processing deficit associated with this genetic variation, since
auditory feedback is crucial for vocal communication.
To further understand the role of heterozygous mutations in USH2A, more
comprehensive phenotyping is required. Liu et al., (2007) characterized the morphological
differences between WT and Ush2a KO mice. Unfortunately (and for reasons understood), HT
mice were not examined. Results from that study show a lack of usherin in the basal cochlea in
Ush2a KO mice, resulting in a disorganized and malformed hair cell bundles. This area of the
cochlea is responsible for hearing high-frequency sounds and, if damaged or underdeveloped,
would explain the high-frequency hearing losing seen in USH2 patients. In both the WT and
Ush2a KO, the middle cochlear was intact. An important follow-up study would be to examine
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the cochlear morphology of Ush2a HT mice. Our evidence implies that Ush2a HT mice would
have disorganized middle or apical basilar membrane and hair cell morphology, which would
explain the low-frequency hearing deficits. Further testing would be needed to support these
claims.
The results presented here are some of the first to show auditory processing impairments
in Ush2a HT mice. However, future studies are required to more accurately detail the
frequency-specific hearing loss in these Ush2a carriers. Our Normal Single Tone task utilized
two frequencies, 15 kHz and 40 kHz. It would be naïve to assume that these are the only two
frequencies that evoke the observed behavioral deficits, and more comprehensive phenotyping is
warranted to determine upper and lower boundaries of the frequency-based loss. In addition to
comparing the structural differences between WT and Ush2a KO cochlear morphology, Liu et
al., (2007) measured mean cochlear thresholds and found Ush2a KO mice showed highfrequency hearing loss (Liu et al.,2007). These same distortion product otoacoustic emissions
(DPOAE) measures could be used on our Ush2a HT mice to determine the specific frequency
range of hearing difficulties. Together, modifications to previously used methods (i.e., altering
the frequency of NST tasks) and the addition of several other auditory related tasks would
provide additional insight into the behavior associated with Ush2a HT mice.
Our results have important clinical implications, especially for individuals who are
carriers of USH2 mutations. Efforts have been made to develop physiological tests and/or
markers for carrier detection but have all failed to accurately identify individuals. These
measures include dark adaption rod/cone thresholds, ophthalmoscopic abnormalities, and speech
discrimination scores (van Aarem et al., 1995; Sondheimer et al., 1979; de Haas et al., 1970).
Based on the results presented above, a better method for accurate carrier detection may be to
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exploit the auditory-evoked startle response. Infants as young as 2 months old have the ability to
perceive and identify rapidly presented acoustic stimuli, an ability necessary for language
development (Aslin et al., 1989; Jensen et al., 1993; Jusczyk et al., 1980). Suspected carriers of
USH2 could be tested for rapid auditory processing impairments using methods illustrated in
Benasich & Tallal (2002). This human task mirrors the higher-order auditory processing tasks
that were used to assess Ush2a HT mouse auditory processing ability and would also (in
humans) provide predictions on later-language outcomes, as rapid auditory processing ability is
known to predict language development (Benasich & Tallal, 2002).
Overall, these findings support the view that USH2A plays a role in APD and possibly
language development. Additional evidence from large human genetic samples suggest that
hearing loss associated with variants in USH2A may act as a modifying risk factor for APD and
language disorders when other language-related mutations are present (UK ALSPAC sample,
Perrino et al., in-prep). Genes implicated appear to cluster to genetic mediation of synaptogenic
and neuronal migration pathways, suggesting a possibility for interaction between low-level
hearing loss associated with variants on a gene not expressed in brain (USH2A), and higher-order
neurodevelopmental gene mutations that do affect the brain, together affecting language
outcomes. These mouse results, however, suggest that even low-level hearing anomalies
associated with altered gene expression in the cochlea, but not the brain, may be sufficient to
developmentally impact more complex and higher-order auditory processing, and even
expressive vocalizations. Future research will continue efforts to tease apart genetic
contributions to hearing, APD, and developmental anomalies of language.
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CONCLUSION
Here we not only confirm that homozygous mutations of USH2A result in high-frequency
hearing loss (similar to Usher syndrome type 2) but provide novel insight into USH2A
heterozygous mutations and associated low-frequency hearing loss and altered communication
ability. Results urge updates to how we approach screening and treatment of individuals with
USH2A variants, and USH carriers.
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Figure 1 – Syllable Repertoire generated by MUPET
Forty unique syllables generated via MUPET analysis. Each syallable was assigned to one of ten
possible categories (Heckman et al., 2016). Only eight of the ten categories were observed in the
current repertoire. The number in the bottom left corner indicates the count of utterances seen
across all subjects.
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Figure 2 – Normal Single Tone (NST) attenuation scores
A main effect of Genotype was found for NST 15kHz [(Overall: 15kHz): F(2,32) = 3.697, p <
0.05], with Ush2a HT mice trending towards worse performance than WTs. There was a
marginally significant effect of Genotype on NST 40kHz [(Overall: 40kHz): F(2,32) = 1.995, p ≤
0.1], with Ush2a KO mice displaying poor performance than WTs. (#p ≤ 0.10, *p < 0.05). Lower
attenuation scores indicate better performance.
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Figure 3 – Embedded Tone (EBT) 0-100 at 10.5kHz averaged across days
A main effect of Genotype was found [(Overall): F(2, 31) = 3.691), p < 0.05]. Ush2a HT mice
showed poorer performance on EBT 0-100 at 10.5 kHz compared to WT controls (p ≤ 0.10), using
NST 15kHz as a covariate. (#p ≤ 0.10, *p < 0.05). Lower attenuation scores indicate better
performance.

21

Figure 4 – Embedded Tone (EBT) 0-10 at 10.5kHz averaged across days
A main effect of Genotype was found [(Overall): F(2, 31) = 4.635, p < 0.05]. Ush2a HT mice
displayed poorer performance on EBT 0-10 at 10.5 kHz compared to WT controls (p ≤ 0.10), using
NST 15kHz as a covariate. (#p ≤ 0.10, *p < 0.05). Lower attenuation scores indicate better
performance.
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Figure 5 - Embedded Tone (EBT) 0-10 at 40kHz averaged across days
No main effect of Genotype was observed [(Overall): F(2, 31) = 0.948, p > 0.05]. (N.S = nonsignificant). Lower attenuation scores indicate better performance.

23

Figure 6 - Pitch Discrimination (PD) at 10.5kHz averaged across days
No main effect of Genotype was observed [(Overall): F(2, 31) = 1.325, p > 0.05]. (N.S = nonsignificant). Lower attenuation scores indicate better performance.
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Figure 7 – Pitch Discrimination (PD) at 40kHz averaged across days
No significant effect of Genotype was found [(Overall): F(2, 31) = 2.335, p > 0.05]. Ush2a KO
mice, however, displayed poorer performance on PD at 40 kHz compared to WT controls (p <
0.01), using NST 40kHz as a covariate. (N.S = non-significant, **p < 0.01). Lower attenuation
scores indicate better performance.
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Figure 8 – Silent Gap (SG) 0-300ms averaged across days
No main effect of Genotype was observed [(Overall): F(2, 31) = 2.497, p > 0.05]. (N.S = nonsignificant). Lower attenuation scores indicate better performance.
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Figure 9 - Silent Gap (SG) 0-100ms averaged across days
No main effect of Genotype was observed [(Overall): F(2, 31) = 1.378, p > 0.05]. (N.S = nonsignificant). Lower attenuation scores indicate better performance.
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Figure 10 – Ultrasonic Vocalizations (USVs) - Time Spent Vocalizing
(A) No significant effects of Genotype were found on mean time spent vocalizing when collapsed
by category. (B) No significant effects of Genotype were found on time spent vocalizing for
individual categories.
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Figure 11 – Ultrasonic Vocalizations (USVs) – Mean Number of Calls
(A) No significant effects of Genotype were found on mean number of calls when collapsed by
category. (B) No significant effects of Genotype were found on number of calls for individual
categories.
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Figure 12 – Ultrasonic Vocalizations (USVs) – Syllable Duration
(A) Overall, Ush2a HT mice produced significantly shorter syllables when compared to WT mice
[(Overall) F(2, 16100) = 26.70, p < 0.05]. (B) Ush2a HT mice produced significantly shorter Short,
Down-FM, Up-FM syllables when compared to WT mice. However, Ush2a HT mice produced
longer Complex syllables when compared to WT mice. (*p < 0.05, ***p < 0.001).
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Figure 13 – Ultrasonic Vocalizations (USVs) – Syllable Volume
(A) Overall, Ush2a HT mice produced significantly louder syllables when compared to WT mice
[(Overall) F(2, 16100) = 142.54, p < 0.05]. (B) Ush2a HT mice produced significantly louder
Short, Down-FM, Chevron, and Noisy syllables when compared to WT mice. (*p < 0.05, ***p <
0.001).
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Figure 14 – Ultrasonic Vocalizations (USVs) – Mean Syllable Frequency
(A) Overall, Ush2a HT mice produced syllables at significantly higher frequencies when compared
to WT mice [(Overall) F(2, 16100) = 87.476, p < 0.05]. (B) Ush2a HT mice produced significantly
higher Short, Down-FM, Up-FM, Chevron, Flat, Noisy, and Complex syllables when compared to
WT mice. (#p ≤ 0.10, *p < 0.05, ***p < 0.001).
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Table 1 – Statistics summarizing Genotype effect for syllable duration by each call type (df, F, p).
p values for WT vs. HT and WT vs. KO comparisons provided. Yellow: significant at  = 0.05;
Green: significant at  = 0.10.
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Table 2 – Statistics summarizing Genotype effect for syllable volume by each call type (df, F, p).
p values for WT vs. HT and WT vs. KO comparisons provided. Yellow: significant at  = 0.05;
Green: significant at  = 0.10.
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Table 3 – Statistics summarizing Genotype effect for syllable frequency by each call type (df, F,
p). p values for WT vs. HT and WT vs. KO comparisons provided. Yellow: significant at  =
0.05; Green: significant at  = 0.10.
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